Table 5.

Sensitivity analysis for postrecurrence risk of metastasis with different HRs relative to those estimated based on the JHU cohort with PSA recurrence who did not get salvage treatment

HR applied on JHU cohortLower bound on percent overdetected if PSA recurrence within 5 years after RP (%)Lower bound on percent overdetected if PSA recurrence within 5–10 years after RP (%)
2.007.9 (6.4–9.4)13.7 (10.8–16.5)
1.508.7 (7.3–10.2)14.5 (11.6–17.4)
1.258.9 (7.4–10.5)15.4 (12.4–18.3)
1.009.1 (7.6–10.6)15.6 (12.6–18.5)
0.7510.3 (8.7–11.8)16.5 (13.7–19.2)
0.5010.8 (9.2–12.4)16.9 (13.8–20.1)
0.2511.6 (9.8–13.4)17.8 (14.6–20.9)